CompletedNCT01700829
Ketamine Compared With Midazolam for Suicidal Thoughts in Depression
About this title
Read the official source — NCT01700829Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJune 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 82
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01700829
- Official title
Show the full official title
Ketamine vs. Midazolam: Testing Rapid Relief of Suicide Risk in Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including ketamine and Midazolam.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
